Resveratrol improves blood sugar control in type 2 diabetes patients: Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-11-02 03:30 GMT   |   Update On 2021-11-02 03:30 GMT

Egypt: According to a recent study in the journal Medicina Clínica, resveratrol supplementation results in better blood sugar control and improves cardiometabolic parameters in patients with type 2 diabetes mellitus (T2DM). Resveratrol is a natural phenol and phytoalexin produced by plants.T2DM is a progressive meta-inflammatory disorder that leads to micro and macrovascular...

Login or Register to read the full article

Egypt: According to a recent study in the journal Medicina Clínica, resveratrol supplementation results in better blood sugar control and improves cardiometabolic parameters in patients with type 2 diabetes mellitus (T2DM). Resveratrol is a natural phenol and phytoalexin produced by plants.

T2DM is a progressive meta-inflammatory disorder that leads to micro and macrovascular complications. Resveratrol is a nutraceutical that is known to have anti-inflammatory and antioxidant properties. It improves insulin resistance however, there is no clear evidence of its effects in T2D patients. To clarify the same, Ibrahim A.Abdelhaleem, International Medical Research Association IMedRA, Egypt, and colleagues aimed to evaluate the safety and efficacy of oral resveratrol supplementation in type 2 diabetic patients concerning dose and duration.

For this purpose, the researchers searched the online databases for RCTs that evaluated the efficacy and safety of resveratrol on patients with T2DM. The researchers screened the studies for the eligibility criteria, performed the quality assessment, extracted the studies' characteristics, baseline, and outcome data of interest, and finally conducted the meta-analysis using RevManV5.3. 

The systematic review and meta-analysis included 17 RCTs with a total of 871 patients with T2DM. 

The study revealed the following findings:

  • The pooled effect estimate did not favor resveratrol over placebo with doses of less than 500 mg in fasting blood glucose, fasting serum insulin, and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). However, the higher doses of resveratrol (≥500 mg) were superior to placebo regarding these parameters.
  • Concerning HbA1c and systolic blood pressure, the subgroup analyses showed that the pooled effect estimate favored resveratrol over placebo at three months.

The researchers concluded that resveratrol beneficially modulates glycemic control as well as cardiometabolic parameters in patients with T2DM.

Reference:

The study titled, "The effects of resveratrol on glycemic control and cardiometabolic parameters in patients with T2DM: A systematic review and meta-analysis," is published in the journal Medicina Clínica. 

DOI: https://www.sciencedirect.com/science/article/abs/pii/S0025775321004723

Tags:    
Article Source : Medicina Clínica

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News